3SBio's (HKG:1530) attributable profit rose 35% to 2.09 billion yuan in 2024 from 1.55 billion yuan in 2023, according to a Tuesday filing with the Hong Kong bourse.
Earnings per share at the biopharmaceutical company increased to 0.85 yuan from 0.62 yuan a year earlier. Analysts at Visible Alpha estimated EPS per share at 0.83 yuan.
Revenue grew 17% to 9.11 billion yuan from 7.82 billion yuan in the previous year. Visible Alpha analysts forecast revenue at 8.90 billion yuan.
The company declared a final dividend of HK$0.25 per share, payable Aug. 15 to shareholders on record as of July 25.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.